From the Yahoo board, Good Mention of SPORT
"TransEnterix (TRXC), announced it had submitted its 510k application for its SurgiBot system. We anticipate the system will reach the U.S. market in early 2016 and likely see generate some uptake that historically would have gone to Intuitive (specifically in gall bladder cases). That said, we believe the impact will be fairly modest and view SurgiBot as more market expanding than share taking given the unique features of da Vinci and relatively similar price points.
Main Difference in the System Suggests Market Expansion More so Than Direct Competition. We attended TransEnterix analyst day at SAGES 2015, in Nashville. The company’s strategy is to target the roughly 2 million laparoscopic procedures done in the U.S., starting with cholecystectomy. Some of the main differences when comparing the da Vinci and Surgibot include: the surgeon is scrubbed-in (thus in the sterile field in case something goes wrong), cost of the system will be around $500,000 (compared to da Vinci at $1M to $2M depending on the system), a single port incision the size of a quarter, minimizing patient scarring (compared to da Vinci at 5 ports), and its smaller system easily repositioned for multi-quadrant surgery. The company believes the laparoscopic feel of the SurgiBot will be an easy transition for physicians used to performing those surgeries and thus a smaller learning curve. Also, given the cost, size and minimal staff needed to use the system, the company believes it will be an attractive alternative to Small/Mid-size hospitals and surgery centers.
Though the SurgiBot is not a direct competitor (we view Titan Medical’s Sport as a more direct competitor), in our opinion, it could limit some future growth opportunities for Intuitive Surgical and does bring some additional headline risk going forward." Less
News 
Market Data 
Discover 
AI
